185 related articles for article (PubMed ID: 37439384)
41. Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement.
Tong AW; Lee JC; Fay JW; Stone MJ
Blood; 1987 Nov; 70(5):1482-9. PubMed ID: 3663943
[TBL] [Abstract][Full Text] [Related]
42. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
Asosingh K; Menu E; Van Valckenborgh E; Vande Broek I; Van Riet I; Van Camp B; Vanderkerken K
Clin Exp Metastasis; 2002; 19(7):583-91. PubMed ID: 12498387
[TBL] [Abstract][Full Text] [Related]
44. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
Asosingh K
Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
[TBL] [Abstract][Full Text] [Related]
45. Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.
Xu L; Mohammad KS; Wu H; Crean C; Poteat B; Cheng Y; Cardoso AA; Machal C; Hanenberg H; Abonour R; Kacena MA; Chirgwin J; Suvannasankha A; Srour EF
Cancer Res; 2016 Dec; 76(23):6901-6910. PubMed ID: 27634757
[TBL] [Abstract][Full Text] [Related]
46. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
47. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
48. Multiple myeloma and secondary plasma cell leukemia.
Dos Santos VM; Melim SP; de Faria PS; Passini VV; Duarte ML; Casasanta RA
Rom J Morphol Embryol; 2016; 57(2 Suppl):837-839. PubMed ID: 27833979
[TBL] [Abstract][Full Text] [Related]
49. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.
Zheng Y; Yang J; Qian J; Qiu P; Hanabuchi S; Lu Y; Wang Z; Liu Z; Li H; He J; Lin P; Weber D; Davis RE; Kwak L; Cai Z; Yi Q
Leukemia; 2013 Mar; 27(3):702-10. PubMed ID: 22996336
[TBL] [Abstract][Full Text] [Related]
50. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
51. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
[TBL] [Abstract][Full Text] [Related]
52. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
53. Homing mechanisms in the biology of multiple myeloma.
Van Camp B; Van Riet I
Verh K Acad Geneeskd Belg; 1998; 60(3):163-94. PubMed ID: 9803879
[TBL] [Abstract][Full Text] [Related]
54. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
[TBL] [Abstract][Full Text] [Related]
55. FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma.
Zhang W; Wu C; Geng S; Wang J; Yan C; Zhang X; Zhang JJ; Wu F; Pang Y; Zhong Y; Wang J; Fu W; Huang X; Wang W; Lyu X; Huang Y; Jing H
Aging (Albany NY); 2023 May; 15(9):3644-3677. PubMed ID: 37155154
[TBL] [Abstract][Full Text] [Related]
56. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
57. [The mechanisms of myeloma cell growth].
Shimizu S
Nihon Rinsho; 1995 Mar; 53(3):557-63. PubMed ID: 7699885
[TBL] [Abstract][Full Text] [Related]
58. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
59. Homing of the myeloma cell clone.
Vanderkerken K; Van Camp B; De Greef C; Vande Broek I; Asosingh K; Van Riet I
Acta Oncol; 2000; 39(7):771-6. PubMed ID: 11145431
[TBL] [Abstract][Full Text] [Related]
60. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
Cheung WC; Van Ness B
Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
